The modulatory role of dopamine in anxiety-like behavior

Archives of Iranian Medicine

Volumn 18, Issue 9, 2015, Pages 591-603

  Zarrindast, Mohammad Reza ^a,b,c,d,e   Khakpai, Fatemeh ^e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d INSTITUTE FOR RESEARCH IN FUNDAMENTAL SCIENCES IPM   (Iran)

^e INSTITUTE FOR COGNITIVE SCIENCE STUDIES ICSS   (Iran)

Author keywords

Anxiety; D1 and D2 receptor; Dopamine; Mesocortical; Nigrostriatal

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; ETICLOPRIDE; HISTAMINE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OPIATE RECEPTOR; QUINPIROLE; RACLOPRIDE; SULPIRIDE; CANNABINOID RECEPTOR; DOPAMINE RECEPTOR; GLUTAMATE RECEPTOR;

AMYGDALOID NUCLEUS; ANXIETY; BASOLATERAL AMYGDALA; CHOLINERGIC NERVE; CHOLINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; GABAERGIC SYSTEM; HIPPOCAMPUS; LATERODORSAL TEGMENTAL NUCLEUS; LOCOMOTION; MEDIAL PREFRONTAL CORTEX; MESOLIMBIC DOPAMINERGIC SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; PREFRONTAL CORTEX; REVIEW; VENTRAL PALLIDUM; ANIMAL; CHOLINERGIC NERVE CELL; CYTOLOGY; DOPAMINERGIC NERVE CELL; HUMAN; LIMBIC SYSTEM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANXIETY; CHOLINERGIC NEURONS; DOPAMINE; DOPAMINERGIC NEURONS; HUMANS; LIMBIC SYSTEM; RECEPTORS, CANNABINOID; RECEPTORS, DOPAMINE; RECEPTORS, GLUTAMATE; RECEPTORS, HISTAMINE;

EID: 84940193870     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Review

References (233)

1. Veening JG, Bocker KB, Verdouw PM, Olivier B, De Jongh R, Groe-nink L. Activation of the septohippocampal system differentiates anxiety from fear in startle paradigms. Neuroscience. 2009; 163(4): 1046-1060.
2. Khakpai F. The effect of opiodergic sstem and testosterone on anxiety behavior in gonadectomized rats. Behav Brain Res. 2014; 263: 9-15.
3. Pego JM, Sousa JC, Almeida OF, Sousa N. Stress and the neuroen-docrinology of anxiety disorders. Curr Top Behav Neurosci. 2010; 2: 97-117.
4. Shin LM, Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology. 2010; 35(1): 169-191.
5. Leuner B, Shors TJ. Stress, anxiety, and dendritic spines: What are the connections? Neuroscience. 2012.
6. Gray JA, Mcnaughton N. The neuropsychology of anxiety: reprise. Nebr Symp Motiv. 1996; 43: 61-134.
7. Blanchard RJ, Blanchard DC. Attack and defense in rodents as etho-experimental models for the study of emotion. Prog Neuropsycho-pharmacol Biol Psychiatry. 1989; 13 (Suppl): 3-14.
8. Walker DL, Toufexis DJ, Davis M. Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur J Pharmacol. 2003; 463(1 - 3): 199-216.
9. Canteras NS, Resstel LB, Bertoglio LJ, Carobrez Ade P, Guimaraes FS. Neuroanatomy of anxiety. Curr Top Behav Neurosci. 2010; 2: 77-96.
10. De La Mora MP, Gallegos-Cari A, Arizmendi-Garcia Y, Marcellino D, Fuxe K. Role of dopamine receptor mechanisms in the amygdaloid modulation of fear and anxiety: Structural and functional analysis. ProgNeurobiol. 2010; 90(2): 198-216.
11. Kienast T, Hariri AR, Schlagenhauf F, Wrase J, Sterzer P, Buchholz HG, et al. Dopamine in amygdala gates limbic processing of aversive stimuli in humans. Nat Neurosci. 2008; 11(12): 1381-1382.
12. Diaz MR, Chappell AM, Christian DT, Anderson NJ, Mccool BA. Dopamine D3-like receptors modulate anxiety - like behavior and regulate GABAergic transmission in the rat lateral/basolateral amygdala. Neuropsychopharmacology. 2011; 36(5): 1090-1103.
13. Lesch KP, Zeng Y, Reif A, Gutknecht L. Anxiety-related traits in mice with modified genes of the serotonergic pathway. Eur J Pharmacol. 2003; 480(1 - 3): 185-204.
14. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav. 2005; 81(2): 331-342.
15. Rostami P, Hajizadeh-Moghaddam A, Zarrindast MR. The effects of histaminergic agents in the ventral hippocampus of rats in the plus-maze test of anxiety-like behaviours. Physiol Behav. 2006; 87(5): 891-896.
16. Ashabi G, Oryan S, Ahmadi R, Valizadegan F. The effects of hip-pocampal opioidergic and septal GABAergic system interactions on anxiety-like behavior in rats. Life Sci. 2011; 89(21 - 22): 821-826.
17. Zarrindast MR, Nasehi M, Khansari M, Bananej M. Influence of nitric oxide agents in the rat amygdala on anxiogenic-like effect induced by histamine. Neurosci Lett. 2011; 489(1): 38-42.
18. Palomares-Castillo E, Hernandez-Perez OR, Perez-Carrera D, Crespo-Ramirez M, Fuxe K, Perez De La Mora M. The intercalated paracapsular islands as a module for integration of signals regulating anxiety in the amygdala. Brain Res. 2012; 1476: 211-234.
19. Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, Olive-ra-Lopez JI, Jaramillo MT. Antidepressant-like and anxiolytic - like actions of the mGlu5 receptor antagonist MTEP, microinjected into lateral septal nuclei of male Wistar rats. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(6): 1129-1135.
20. Zarrindast MR, Valizadegan F, Rostami P, Rezayof A. Histaminergic system of the lateral septum in the modulation of anxiety-like behaviour in rats. Eur J Pharmacol. 2008; 583(1): 108-114.
21. Peleg-Raibstein D, Pezze MA, Ferger B, Zhang WN, Murphy CA, Feldon J, et al. Activation of dopaminergic neurotransmission in the medial prefrontal cortex by N-methyl-d-aspartate stimulation of the ventral hippocampus in rats. Neuroscience. 2005; 132(1): 219-232.
22. Fogaca MV, Aguiar DC, Moreira FA, Guimaraes FS. The endocan-nabinoid and endovanilloid systems interact in the rat prelimbic medial prefrontal cortex to control anxiety-like behavior. Neuropharma-cology. 2012; 63(2): 202-210.
23. Zarrindast MR, Babapoor-Farrokhran S, Rezayof A. Involvement of opioidergic system of the ventral hippocampus, the nucleus accum-bens or the central amygdala in anxiety-related behavior. Life Sci. 2008; 82(23 - 24): 1175-1181.
24. Kochenborger L, Zanatta D, Berretta LM, Lopes AP, Wunderlich BL, Januario AC, et al. Modulation of fear/anxiety responses, but not food intake, following alpha - adrenoceptor agonist microinjections in the nucleus accumbens shell of free-feeding rats. Neuropharmacology. 2012; 62(1): 427-435.
25. Adhikari A, Topiwala MA, Gordon JA. Synchronized activity between the ventral hippocampus and the medial prefrontal cortex during anxiety. Neuron. 2010; 65(2): 257-269.
26. Reis FL, Masson S, De Oliveira AR, Brandao ML. Dopaminergic mechanisms in the conditioned and unconditioned fear as assessed by the two-way avoidance and light switch-off tests. Pharmacol Bio-chem Behav. 2004; 79(2): 359-365.
27. Lawford BR, Young R, Noble EP, Kann B, Ritchie T. The D2 dopa- mine receptor (DRD2) gene is associated with co - morbid depression, anxiety and social dysfunction in untreated veterans with post-traumatic stress disorder. Eur Psychiatry. 2006; 21(3): 180-185.
28. Leblanc J, Ducharme MB. Plasma dopamine and noradrenaline variations in response to stress. Physiol Behav. 2007; 91(2 - 3): 208-211.
29. Carvalho JD, De Oliveira AR, Da Silva RC, Brandao ML. A comparative study on the effects of the benzodiazepine midazolam and the dopamine agents, apomorphine and sulpiride, on rat behavior in the two-way avoidance test. Pharmacol Biochem Behav. 2009; 92(2): 351-356.
30. Hostetler CM, Harkey SL, Bales KL. D2 antagonist during development decreases anxiety and infanticidal behavior in adult female prairie voles (Microtus ochrogaster). Behav Brain Res. 2010; 210(1): 127-130.
31. Ferreira TB, Kasahara TM, Barros PO, Vieira MM, Bittencourt VC, Hygino J, et al. Dopamine up - regulates Th17 phenotype from individuals with generalized anxiety disorder. J Neuroimmunol. 2011; 238(1 - 2): 58-66.
32. Zweifel LS, Fadok JP, Argilli E, Garelick MG, Jones GL, Dickerson TM, et al. Activation of dopamine neurons is critical for aversive conditioning and prevention of generalized anxiety. Nat Neurosci. 2011; 14(5): 620-626.
33. Falco AM, Mcdonald CG, Bachus SE, Smith RF. Developmental alterations in locomotor and anxiety-like behavior as a function of D1 and D2 mRNA expression. Behav Brain Res. 2014; 260: 25-33.
34. Hodes GE, Pfau ML, Leboeuf M, Golden SA, Christoffel DJ, Breg-man D, et al. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc Natl AcadSci USA. 2014; 111(45): 16136-16141.
35. Sonsalla PK, Coleman C, Wong LY, Harris SL, Richardson JR Gadad BS, et al. The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinson-ism. Exp Neurol. 2013; 250: 376-383.
36. Villalba RM, Smith Y. Differential striatal spine pathology in Parkinson's disease and cocaine addiction: a key role of dopamine? Neuroscience. 2013; 251: 2-20.
37. Sadeghifar AR, Heshmati AA. Dysplasia epiphysealis hemimelica (trevor syndrome) of talus in a 21-year old woman; case report. Arch Bone Jt Surg. 2014; 2(1): 66-68.
38. Remington G. Alterations of dopamine and serotonin transmission in schizophrenia. Prog Brain Res. 2008; 172: 117-140.
39. Horiguchi M, Hannaway KE, Adelekun AE, Huang M, Jayathilake K, Meltzer HY. D(1) receptor agonists reverse the subchronic phencycli-dine (PCP)-induced novel object recognition (NOR) deficit in female rats. Behav Brain Res. 2013; 238: 36-43.
40. Hoare SR Coldwell MC, Strange PG. Allosteric regulation of rat and human dopamine receptor subtypes: evidence for two binding states for [3H]spiperone. Biochem Soc Trans. 1996; 24(1): 53S.
41. Proenca MB, Dombrowski PA, Da Cunha C, Fischer L, Ferraz AC, Lima MM. Dopaminergic D2 receptor is a key player in the substantia nigra pars compacta neuronal activation mediated by REM sleep deprivation. Neuropharmacology. 2014; 76: 118-126.
42. Socha R, Kodrik D, Zemek R. Stimulatory effects of bioamines nor-epinephrine and dopamine on locomotion of Pyrrhocoris apterus (L.): is the adipokinetic hormone involved? Comp Biochem PhysiolB Biochem MolBiol. 2008; 151(3): 305-310.
43. Medvedev IO, Ramsey AJ, Masoud ST, Bermejo MK, Urs N, Sot-nikova TD, et al. D1 dopamine receptor coupling to PLCbeta regulates forward locomotion in mice. J Neurosci. 2013; 33(46): 18125-18133.
44. Nieoullon A. Dopamine and the regulation of cognition and attention.Prog Neurobiol. 2002; 67(1): 53-83.
45. Nazari-Serenjeh F, Rezayof A, Zarrindast MR. Functional correlation between GABAergic and dopaminergic systems of dorsal hippocampus and ventral tegmental area in passive avoidance learning in rats. Neuroscience. 2011; 196: 104-114.
46. Richardson MP, Strange BA, Dolan RJ. Encoding of emotional memories depends on amygdala and hippocampus and their interactions. Nat Neurosci. 2004; 7(3): 278-285.
47. Labar KS, Cabeza R. Cognitive neuroscience of emotional memory. Nat Rev Neurosci. 2006; 7(1): 54-64.
48. Bari AA, Pierce RC. D1-like and D2 dopamine receptor antagonists administered into the shell subregion of the rat nucleus accumbens decrease cocaine, but not food, reinforcement. Neuroscience. 2005; 135(3): 959-968.
49. Tripp G, Wickens J. Reinforcement, dopamine and rodent models in drug development for ADHD. Neurotherapeutics. 2012; 9(3): 622-634.
50. Billes SK, Simonds SE,Cowley MA. Leptin reduces food intake via a dopamine D2 receptor-dependent mechanism. Mol Metab. 2012; 1(1 - 2): 86-93.
51. De Araujo IE, Ferreira JG, Tellez LA, Ren X,Yeckel CW. The gut-brain dopamine axis: a regulatory system for caloric intake. Physiol Behav. 2012; 106(3): 394-399.
52. Ricci A, Amenta F, Bronzetti E, Felici L, Hussain T, Lokhandwala MF. Age-related changes of dopamine receptor protein immunore-activity in the rat mesenteric vascular tree. Mech Ageing Dev. 2002; 123(5): 537-546.
53. Xu R, Parlow AF, Wang Y. The effects of dopamine and D2 receptor antagonists on pituitary hormone secretion are intact in mice lacking dopamine D2L receptor. Brain Res. 2002; 939(1 - 2): 95-99.
54. Millan MJ. The neurobiology and control of anxious states. Prog Neu-robiol. 2003; 70(2): 83-244.
55. Harris RC, Zhang MZ. Dopamine, the kidney, and hypertension. Curr HypertensRep. 2012; 14(2): 138-143.
56. Carey RM. The intrarenal renin-angiotensin and dopaminergic systems: control of renal sodium excretion and blood pressure. Hypertension. 2013; 61(3): 673-680.
57. Drago A, Crisafulli C, Sidoti A, Serretti A. The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and sero-toninergic systems informs a detailed genetic perspective on depressive phenotypes. ProgNeurobiol. 2011; 94(4): 418-460.
58. Abraham AD, Neve KA, Lattal KM. Dopamine and extinction: a convergence of theory with fear and reward circuitry. Neurobiol Learn Mem. 2014; 108: 65-77.
59. Moe RO, Nordgreen J, Janczak AM, Spruijt BM, Kostal L, Skjerve E, et al. Effects of haloperidol, a dopamine D2 - like receptor antagonist, on reward-related behaviors in laying hens. Physiol Behav. 2011; 102(3 - 4): 400-405.
60. Zweifel LS, Parker JG, Lobb CJ, Rainwater A, Wall VZ, Fadok JP, et al. Disruption of NMDAR-dependent burst firing by dopamine neurons provides selective assessment of phasic dopamine-dependent behavior. ProcNatl AcadSci USA. 2009; 106(18): 7281-7288.
61. Zweifel LS, Aigilli E, Bonci A, Palmiter RD. Role of NMDA receptors in dopamine neurons for plasticity and addictive behaviors. Neuron. 2008; 59(3): 486-496.
62. Morikawa H, Paladini CA. Dynamic regulation of midbrain dopamine neuron activity: intrinsic, synaptic, and plasticity mechanisms. Neuro-science. 2011; 198: 95-111.
63. Cervenka S, Hedman E, Ikoma Y, Djurfeldt DR Ruck C, Halldin C, et al. Changes in dopamine D2-receptor binding are associated to symptom reduction after psychotherapy in social anxiety disorder. Transl Psychiatry. 2012; 2: e120.
64. Nasehi M, Ketabchi M, Khakpai F, Zarrindast MR. The effect of CA1 dopaminergic system in harmaline-induced amnesia. Neuroscience. 2015; 285: 47-59.
65. Jamali - Raeufy N, Nasehi M, Zarrindast MR. Influence of N-methyl D-aspartate receptor mechanism on WIN55,212 - 2 - induced amnesia in rat dorsal hippocampus. Behav Pharmacol. 2011; 22(7): 645-654.
66. Wood PB. Mesolimbic dopaminergic mechanisms and pain control. Pain. 2006; 120(3): 230-234.
67. Coffeen U, Lopez-Avila A, Ortega-Legaspi JM, Del Angel R, Lo-pez-Munoz FJ, Pellicer F. Dopamine receptors in the anterior insular cortex modulate long - term nociception in the rat. Eur J Pain. 2008; 12(5): 535-543.
68. Lemke MR, Brecht HM, Koester J, Reichmann H. Effects of the Adopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci. 2006; 248(1 - 2): 266-270.
69. Porcelli S, Drago A, Fabbri C, Serretti A. Mechanisms of antidepres-sant action: an integrated dopaminergic perspective. Prog Neuropsy-chopharmacol Biol Psychiatry. 2011; 35(7): 1532-1543.
70. Zahm DS, Trimble M. The dopaminergic projection system, basal forebrain macrosystems, and conditioned stimuli. CNS Spectr. 2008; 13(1): 32-40.
71. Forestiero D, Manfrim CM, Guimaraes FS, De Oliveira RM. Anxio-lytic-like effects induced by nitric oxide synthase inhibitors microin-jected into the medial amygdala of rats. Psychopharmacology (Berl). 2006; 184(2): 166-172.
72. Bonomaully M, Khong T, Fotriadou M, Tully J. Anxiety and depression related to elevated dopamine in a patient with multiple mediasti-nal paragangliomas. Gen Hosp Psychiatry. 2014; 36(4): e447-e448.
73. Nasehi M, Piri M, Nouri M, Farzin D, Nayer-Nouri T, Zarrindast MR. Involvement of dopamine D1/D2 receptors on harmane-induced amnesia in the step-down passive avoidance test. Eur J Pharmacol. 2010; 634(1 - 3): 77-83.
74. Zarrindast MR, Naghdi-Sedeh N, Nasehi M, Sahraei H, Bahrami F, Asadi F. The effects of dopaminergic drugs in the ventral hippocampus of rats in the nicotine-induced anxiogenic-like response. Neurosci Lett. 2010; 475(3): 156-160.
75. Alcantara-Gonzalez D, Floran B, Escartin E, Rocha L. Changes on D2-like receptor induced Gi protein activation and hippocampal do-pamine release in kindled rats. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 40: 246-251.
76. Keck TM, Suchland KL, Jimenez CC, Grandy DK. Dopamine D4 receptor deficiency in mice alters behavioral responses to anxiogenic stimuli and the psychostimulant methylphenidate. Pharmacol Bio-chem Behav. 2013; 103(4): 831-841.
77. Rezayof A, Motevasseli T, Rassouli Y, Zarrindast MR. Dorsal hippo-campal dopamine receptors are involved in mediating ethanol state-dependent memory. Life Sci. 2007; 80(4): 285-292.
78. Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev. 2000; 24(1): 125-132.
79. Nasehi M, Mafi F, Oiyan S, Nasri S, Zarrindast MR. The effects of dopaminergic drugs in the dorsal hippocampus of mice in the nicotine-induced anxiogenic-like response. Pharmacol Biochem Behav. 2011; 98(3): 468-473.
80. Herold C, Joshi I, Chehadi O, Hollmann M, Gunturkun O. Plasticity in D1-like receptor expression is associated with different components of cognitive processes. PLoS One. 2012; 7(5): e36484.
81. Ebrahimi-Ghiri M, Nasehi M, Rostami P, Mohseni-Kouchesfehani H, Zarrindast MR. The effect of cholestasis on rewarding and exploratory behaviors induced by opioidergic and dopaminergic agents in mice. Arch Iran Med. 2012; 15(10): 617-624.
82. Wang Y, Harsanyi K, Mangel SC. Endogenous activation of dopamine D2 receptors regulates dopamine release in the fish retina. J Neuro-physiol. 1997; 78(1): 439-449.
83. Zarrindast MR, Azami BN, Rostami P, Rezayof A. Repeated administration of dopaminergic agents in the nucleus accumbens and morphine - induced place preference. Behav Brain Res. 2006; 169(2): 248-255.
84. Walters JR, Bergstrom DA, Carlson JH, Chase TN, Braun AR. D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science. 1987; 236(4802): 719-722.
85. Braun AR, Chase TN. Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors. Eur J Pharmacol. 1986; 131(2 - 3): 301-306.
86. Terzian AL, Drago F, Wotjak CT, Micale V. The Dopamine and Can-nabinoid Interaction in the Modulation of Emotions and Cognition: Assessing the Role of Cannabinoid CB1 Receptor in Neurons Expressing Dopamine D1 Receptors. Front Behav Neurosci. 2011; 5: 49.
87. Perez De La Mora M, Gallegos-Cari A, Crespo-Ramirez M, Marcel-lino D, Hansson AC, Fuxe K. Distribution of dopamine D(2) - like receptors in the rat amygdala and their role in the modulation of unconditioned fear and anxiety. Neuroscience. 2012; 201: 252-266.
88. Bananej M, Karimi-Sori A, Zarrindast MR, Ahmadi S. D1 and D2 dopaminergic systems in the rat basolateral amygdala are involved in anxiogenic - like effects induced by histamine. J Psychopharmacol. 2012; 26(4): 564-574.
89. Matsuda S, Matsuzawa D, Ishii D, Tomizawa H, Sutoh C, Nakazawa K, et al. Effects of perinatal exposure to low dose of bisphenol A on anxiety like behavior and dopamine metabolites in brain. Prog Neuro-psychopharmacol Biol Psychiatry. 2012; 39(2): 273-279.
90. Eskow Jaunarajs KL, George JA, Bishop C. L-DOPA-induced dys-regulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease. Neuroscience. 2012; 218: 243-256.
91. Thiemann G, Watt CA, Ledent C, Molleman A, Hasenohrl RU. Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain. Behav Brain Res. 2009; 200(1): 60-67.
92. Chiavegatto S, Izidio GS, Mendes-Lana A, Aneas I, Freitas TA, Torrao AS, et al. Expression of alpha-synuclein is increased in the hippocampus of rats with high levels of innate anxiety. Mol Psychiatry. 2009; 14(9): 894-905.
93. Pandaranandaka J, Poonyachoti S, Kalandakanond-Thongsong S. Anxiolytic property of estrogen related to the changes of the mono-amine levels in various brain regions of ovariectomized rats. Physiol Behav. 2006; 87(4): 828-835.
94. Melis M, Pistis M. Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. Philos Trans R Soc Lond B Biol Sci. 2012; 367(1607): 3276-3285.
95. Wise RA. Roles for nigrostriatal-not just mesocorticolimbic-dopa-mine in reward and addiction. Trends Neurosci. 2009; 32(10): 517-524.
96. Cohen BN, Mackey ED, Grady SR, Mckinney S, Patzlaff NE, Wage- man CR, et al. Nicotinic cholinergic mechanisms causing elevated dopamine release and abnormal locomotor behavior. Neuroscience. 2012; 200: 31-41.
97. Ford CP, Mark GP, Williams JT. Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J Neurosci. 2006; 26(10): 2788-2797.
98. Margolis EB, Coker AR, Driscoll JR, Lemaitre AI, Fields HL. Reliability in the identification of midbrain dopamine neurons. PLoS One. 2010; 5(12): e15222.
99. Lammel S, Hetzel A, Hackel O, Jones I, Liss B, Roeper J. Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. Neuron. 2008; 57(5): 760-773.
100. Lammel S, Ion DI, Roeper J, Malenka RC. Projection-specific modulation of dopamine neuron synapses by aversive and rewarding stimuli. Neuron. 2011; 70(5): 855-862.
101. Rezayof A, Hosseini SS, Zarrindast MR. Effects of morphine on rat behaviour in the elevated plus maze: the role of central amygdala do-pamine receptors. Behav Brain Res. 2009; 202(2): 171-178.
102. Zarrindast MR, Nasehi M, Pournaghshband M, Yekta BG. Dopami-nergic system in CA1 modulates MK - 801 induced anxiolytic-like responses. Pharmacol Biochem Behav. 2012; 103(1): 102-110.
103. Alcaro A, Huber R, Panksepp J. Behavioral functions of the mesolim-bic dopaminergic system: an affective neuroethological perspective. Brain Res Rev. 2007; 56(2): 283-321.
104. Trainor BC. Stress responses and the mesolimbic dopamine system: social contexts and sex differences. Horm Behav. 2011; 60(5): 457-469.
105. Duterte - Boucher D, Kamenka JM, Costentin J. Comparison of the effects of three indirect dopamine agonists, GK 13, GBR 12783 and dexamphetamine on behavioural tests involving central catecholamin-ergic transmissions. Psychopharmacology (Berl). 1990; 101(3): 344-353.
106. Simon P, Panissaud C, Costentin J. Anxiogenic - like effects induced by stimulation of dopamine receptors. Pharmacol Biochem Behav. 1993; 45(3): 685-690.
107. Carpenter RE, Watt MJ, Forster GL, Overli O, Bockholt C, Renner KJ, et al. Corticotropin releasing factor induces anxiogenic locomotion in trout and alters serotonergic and dopaminergic activity. Horm Behav. 2007; 52(5): 600-611.
108. De Manzano O, Cervenka S, Jucaite A, Hellenas O, Farde L, Ullen F. Individual differences in the proneness to have flow experiences are linked to dopamine D2-receptor availability in the dorsal striatum. Neuroimage. 2013; 67: 1-6.
109. Kelley AE, Berridge KC. The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci. 2002; 22(9): 3306-3311.
110. Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci. 2004; 5(6): 483-494.
111. Margolis EB, Lock H, Hjelmstad GO, Fields HL. The ventral tegmen-tal area revisited: is there an electrophysiological marker for dopami-nergic neurons? J Physiol. 2006; 577(3): 907-924.
112. Zarrindast MR, Eslahi N, Rezayof A, Rostami P, Zahmatkesh M. Modulation of ventral tegmental area dopamine receptors inhibit nico- tine - induced anxiogenic-like behavior in the central amygdala. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 41: 11-17.
113. O'donnell P. Dopamine gating of forebrain neural ensembles. Eur J Neurosci. 2003; 17(3): 429-435.
114. Adell A, Artigas F. The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems. Neurosci Biobehav Rev. 2004; 28(4): 415-431.
115. Ding ZM, Liu W, Engleman EA, Rodd ZA and Mcbride WJ. Differential effects of dopamine D2 and GABA(A) receptor antagonists on do-pamine neurons between the anterior and posterior ventral tegmental area of female Wistar rats. Pharmacol Biochem Behav. 2009; 92(3): 404-412.
116. Radke AK, Gewirtz JC. Increased dopamine receptor activity in the nucleus accumbens shell ameliorates anxiety during drug withdrawal. Neuropsychopharmacology. 2012; 37(11): 2405-2415.
117. Mahmoodi G, Ahmadi S, Pourmotabbed A, Oryan S, Zarrindast MR. Inhibitory avoidance memory deficit induced by scopolamine: Interaction of cholinergic and glutamatergic systems in the ventral tegmental area. NeurobiolLearn Mem. 2010; 94(1): 83-90.
118. Modol L, Darbra S, Pallares M. Neurosteroids infusion into the CA1 hippocampal region on exploration, anxiety-like behaviour and aver-sive learning. Behav Brain Res. 2011; 222(1): 223-229.
119. Nasehi M, Tabatabaie M, Khakpai F, Zarrindast MR. The effects of CA1 5HT4 receptors in MK801-induced amnesia and hyperlocomo- tion. Neurosci Lett. 2015; 587: 73-78.
120. Rezvanfard M, Zarrindast MR, Bina P. Role of ventral hippocampal GABA(A) and NMDA receptors in the anxiolytic effect of carbam-azepine in rats using the elevated plus maze test. Pharmacology. 2009; 84(6): 356-366.
121. Solati J. Dorsal hippocampal N-methyl-D-aspartate glutamatergic and delta-opioidergic systems modulate anxiety behaviors in rats in a noninteractive manner. Kaohsiung J Med Sci. 2011; 27(11): 485-493.
122. Sun QJ, Duan RS, Wang AH, Shang W, Zhang T, Zhang XQ, et al. Alterations of NR2B and PSD-95 expression in hippocampus of kainic acid - exposed rats with behavioural deficits. Behav Brain Res. 2009; 201(2): 292-299.
123. Khakpai F, Nasehi M, Haeri-Rohani A, Eidi A, Zarrindast MR. Sep-to-hippocampo- septal loop and memory formation. Basic Clin Neu-rosci. 2013; 4(1): 5-23.
124. Nasehi M, Mashaghi E, Khakpai F, Zarrindast MR. Suggesting a possible role of CA1 histaminergic system in harmane-induced amnesia. Neurosci Lett. 2013; 556: 5-9.
125. Nasehi M, Jamshidi-Mehr M, Khakpai F, Zarrindast MR. Possible involvement of CA1 5-HT1B/1D and 5-HT2A/2B/2C receptors in harmaline-induced amnesia. Pharmacol Biochem Behav. 2014; 125: 70-77.
126. Calixto AV, Duarte FS, Duzzioni M, Nascimento Hackl LP, Faria MS, De Lima TC. Role of ventral hippocampal nitric oxide/cGMP pathway in anxiety-related behaviors in rats submitted to the elevated T-maze. Behav Brain Res. 2010; 207(1): 112-117.
127. Nasehi M, Kafi F, Khakpai F, Zarrindast MR. Involvement of the serotonergic system of the ventral hippocampus (CA3) on amnesia induced by ACPA in mice. Behav Brain Res. 2015; 286: 356-363.
128. Zarrindast MR, Dorrani M, Lachinani R, Rezayof A. Blockade of dorsal hippocampal dopamine receptors inhibits state - dependent learning induced by cannabinoid receptor agonist in mice. Neurosci Res. 2010; 67(1): 25-32.
129. Tran AH, Uwano T, Kimura T, Hori E, Katsuki M, Nishijo H, et al. Dopamine D1 receptor modulates hippocampal representation plasticity to spatial novelty. J Neurosci. 2008; 28(50): 13390-13400.
130. Bast T, Feldon J. Hippocampal modulation of sensorimotor processes. Prog Neurobiol. 2003; 70(4): 319-345.
131. Zarrindast MR, Sarahroodi S, Arzi A, Khodayar MJ, Taheri-Shalmani S, Rezayof A. Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behavior: interaction with the opioid system. Be-havPharmacol. 2008; 19(7): 716-723.
132. Zarrindast MR, Solati J, Oryan S, Parivar K. Effect of intra-amygdala injection of nicotine and GABA receptor agents on anxiety-like behaviour in rats. Pharmacology. 2008; 82(4): 276-284.
133. Flandreau EI, Ressler KJ, Owens MJ, Nemeroff CB. Chronic overex-pression of corticotropin-releasing factor from the central amygdala produces HPA axis hyperactivity and behavioral anxiety associated with gene-expression changes in the hippocampus and paraventricu-lar nucleus of the hypothalamus. Psychoneuroendocrinology. 2012; 37(1): 27-38.
134. Walf AA, Frye CA. A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. Neuropsychopharmacology. 2006; 31(6): 1097-1111.
135. Lesscher HM, Mcmahon T, Lasek AW, Chou WH, Connolly J, Khara-zia V, et al. Amygdala protein kinase C epsilon regulates corticotro-pin-releasing factor and anxiety-like behavior. Genes Brain Behav. 2008; 7(3): 323-333.
136. McEwen BS, Eiland L, Hunter RG, Miller MM. Stress and anxiety: structural plasticity and epigenetic regulation as a consequence of stress. Neuropharmacology. 2012; 62(1): 3-12.
137. Izumo N, Ishibashi Y, Ohba M, Morikawa T, Manabe T. Decreased voluntary activity and amygdala levels of serotonin and dopamine in ovariectomized rats. Behav Brain Res. 2012; 227(1): 1-6.
138. Roozendaal B, Mcewen BS, Chattarji S. Stress, memory and the amygdala. Nat Rev Neurosci. 2009; 10(6): 423-433.
139. De Jesus-Burgos M, Torres-Llenza V, Perez-Acevedo NL. Activation of amygdalar metabotropic glutamate receptors modulates anxiety, and risk assessment behaviors in ovariectomized estradiol-treated female rats. Pharmacol Biochem Behav. 2012; 101(3): 369-378.
140. Mitra R, Sapolsky RM. Acute corticosterone treatment is sufficient to induce anxiety and amygdaloid dendritic hypertrophy. Proc Natl Acad Sci USA. 2008; 105(14): 5573-5578.
141. Mitra R, Adamec R, Sapolsky R. Resilience against predator stress and dendritic morphology of amygdala neurons. Behav Brain Res. 2009; 205(2): 535-543.
142. Qin M, Xia Z, Huang T, Smith CB. Effects of chronic immobilization stress on anxiety-like behavior and basolateral amygdala morphology in Fmr1 knockout mice. Neuroscience. 2011; 194: 282-290.
143. Engin E, Treit D. The effects of intra-cerebral drug infusions on animals' unconditioned fear reactions: A systematic review. Prog Neuro-psychopharmacol Biol Psychiatry. 2008; 32(6): 1399-1419.
144. Zarrindast MR, Sroushi A, Bananej M, Vousooghi N, Hamidkhaniha S. Involvement of the dopaminergic receptors of the rat basolateral amygdala in anxiolytic-like effects of the cholinergic system. Eur J Pharmacol. 2011; 672(1 - 3): 106-112.
145. Marowsky A, Yanagawa Y, Obata K, Vogt KE. A specialized subclass of interneurons mediates dopaminergic facilitation of amygdala function. Neuron. 2005; 48(6): 1025-1037.
146. Kupferschmidt DA, Newman AE, Boonstra R, Erb S. Antagonism of cannabinoid 1 receptors reverses the anxiety-like behavior induced by central injections of corticotropin-releasing factor and cocaine withdrawal. Neuroscience. 2012; 204: 125-133.
147. De Oliveira AR, Reimer AE, De Macedo CE, De Carvalho MC, Silva MA, Brandao ML. Conditioned fear is modulated by D2 receptor pathway connecting the ventral tegmental area and basolateral amygdala. Neurobiol Learn Mem. 2011; 95(1): 37-45.
148. Balaban CD, Thayer JF. Neurological bases for balance-anxiety links. J Anxiety Disord. 2001; 15(1 - 2): 53-79.
149. Yousefi B, Nasehi M, Khakpai F, Zarrindast MR. Possible interaction of cholinergic and GABAergic systems between MS and CA1 upon memory acquisition in rats. Behav Brain Res. 2012; 235(2): 231-243.
150. De Paula DC, Torricelli AS, Lopreato MR, Nascimento JO, Viana MB. 5-HT(2A) receptor activation in the dorsolateral septum facilitates inhibitory avoidance in the elevated T-maze. Behav Brain Res. 2012; 226(1): 50-55.
151. Lamprea MR, Garcia AM, Morato S. Effects of reversible inactivation of the medial septum on rat exploratory behavior in the elevated plus-maze using a test-retest paradigm. Behav Brain Res. 2010; 210(1): 67-73.
152. Lecourtier L, De Vasconcelos AP, Cosquer B, Cassel JC. Combined lesions of GABAergic and cholinergic septal neurons increase loco-motor activity and potentiate the locomotor response to amphetamine. Behav Brain Res. 2010; 213(2): 175-182.
153. Khakpai ZM, Nasehi M, Haeri-Rohani A, Eidi A. The role of gluta-matergic pathway between septum and hippocampus in the memory formation. EXCLI Journal. 2013; 12: 41-51.
154. Khakpai F, Nasehi M, Haeri-Rohani A, Eidi A, Zarrindast MR. Sco-polamine induced memory impairment; possible involvement of NMDA receptor mechanisms of dorsal hippocampus and/or septum. Behav Brain Res. 2012; 231(1): 1-10.
155. Trent NL, Menard JL. Infusions of neuropeptide Y into the lateral septum reduce anxiety-related behaviors in the rat. Pharmacol Biochem Behav. 2011; 99(4): 580-590.
156. Calfa G, Bussolino D, Molina VA. Involvement of the lateral septum and the ventral Hippocampus in the emotional sequelae induced by social defeat: role of glucocorticoid receptors. Behav Brain Res. 2007;181(1): 23-34.
157. Trent NL, Menard JL. The ventral hippocampus and the lateral septum work in tandem to regulate rats' open - arm exploration in the elevated plus-maze. Physiol Behav. 2010; 101(1): 141-152.
158. Zarrindast MR, Ardjmand A, Ahmadi S, Rezayof A. Activation of dopamine D1 receptors in the medial septum improves scopolamine -induced amnesia in the dorsal hippocampus. Behav Brain Res. 2012; 229(1): 68-73.
159. Adams BW, Moghaddam B. Tactile stimulation activates dopamine release in the lateral septum. Brain Res. 2000; 858(1): 177-180.
160. Gutierrez-Garcia AG, Contreras CM, Diaz-Meza JL, Bernal-Morales B, Rodriguez-Landa JF, Saavedra M. Intraaccumbens dopaminergic lesion suppresses desipramine effects in the forced swim test but not in the neuronal activity of lateral septal nucleus. Prog Neuropsycho-pharmacol Biol Psychiatry. 2003; 27(5): 809-818.
161. Peters J, Thoma P, Koch B, Schwarz M, Daum I. Impairment of verbal recollection following ischemic damage to the right anterior hippocampus. Cortex. 2009; 45(5): 592-601.
162. Sotres-Bayon F, Quirk GJ. Prefrontal control of fear: more than just extinction. Curr Opin Neurobiol. 2010; 20(2): 231-235.
163. Zarrindast MR, Nouri M, Ahmadi S. Cannabinoid CB1 receptors of the dorsal hippocampus are important for induction of conditioned place preference (CPP) but do not change morphine CPP. Brain Res. 2007; 1163: 130-137.
164. Janhunen S, Ahtee L. Differential nicotinic regulation of the nigros-triatal and mesolimbic dopaminergic pathways: implications for drug development. Neurosci Biobehav Rev. 2007; 31(3): 287-314.
165. Goto Y, Yang CR, Otani S. Functional and dysfunctional synaptic plasticity in prefrontal cortex: roles in psychiatric disorders. Biol Psychiatry. 2010; 67(3): 199-207.
166. Broersen LM, Abbate F, Feenstra MG, De Bruin JP, Heinsbroek RP, Olivier B. Prefrontal dopamine is directly involved in the anxiogenic interoceptive cue of pentylenetetrazol but not in the interoceptive cue of chlordiazepoxide in the rat. Psychopharmacology (Berl). 2000; 149(4): 366-376.
167. Wall PM, Blanchard RJ, Markham C, Yang M, Blanchard DC. In- fralimbic D1 receptor agonist effects on spontaneous novelty exploration and anxiety-like defensive responding in CD-1 mice. Behav Brain Res. 2004; 152(1): 67-79.
168. Wall PM, Messier C. Concurrent modulation of anxiety and memory. Behav Brain Res. 2000; 109(2): 229-241.
169. Lauzon NM, Bechard M, Ahmad T, Laviolette SR. Supra-normal stimulation of dopamine D1 receptors in the prelimbic cortex blocks behavioral expression of both aversive and rewarding associative memories through a cyclic-AMP-dependent signaling pathway. Neu-ropharmacology. 2013; 67: 104-114.
170. Martinez G, Ropero C, Funes A, Flores E, Blotta C, Landa AI, et al. Effects of selective NMDA and non-NMDA blockade in the nucleus accumbens on the plus-maze test. Physiol Behav. 2002; 76(2): 219-224.
171. Bailer UF, Narendran R, Frankle WG, Himes ML, Duvvuri V, Mathis CA, et al. Amphetamine induced dopamine release increases anxiety in individuals recovered from anorexia nervosa. Int J Eat Disord. 2012; 45(2): 263-271.
172. Ikemoto S. Brain reward circuitry beyond the mesolimbic dopamine system: A neurobiological theory. Neurosci Biobehav Rev. 2010; 35(2): 129-150.
173. Xia Y, Driscoll JR, Wilbrecht L, Margolis EB, Fields HL, Hjelmstad GO. Nucleus accumbens medium spiny neurons target non - dopami-nergic neurons in the ventral tegmental area. J Neurosci. 2011; 31(21): 7811-7816.
174. Christoffel DJ, Golden SA, Dumitriu D, Robison AJ, Janssen WG, Ahn HF, et al. IkappaB kinase regulates social defeat stress - induced synaptic and behavioral plasticity. J Neurosci. 2011; 31(1): 314-321.
175. Yang KC, Jin GZ, Wu J. Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology. Acta Pharmacol Sin. 2009; 30(6): 740-751.
176. Geisler S, Derst C, Veh RW, Zahm DS. Glutamatergic afferents of the ventral tegmental area in the rat. J Neurosci. 2007; 27(21): 5730-5743.
177. Matsuda W, Furuta T, Nakamura KC, Hioki H, Fujiyama F, Arai R, et al. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci. 2009; 29(2): 444-453.
178. Fujiyama F, Sohn J, Nakano T, Furuta T, Nakamura KC, Matsuda W, et al. Exclusive and common targets of neostriatofugal projections ofrat striosome neurons: a single neuron - tracing study using a viral vector. Eur J Neurosci. 2011; 33(4): 668-677.
179. Omelchenko N, Sesack SR. Ultrastructural analysis of local collaterals of rat ventral tegmental area neurons: GABA phenotype and synapses onto dopamine and GABA cells. Synapse. 2009; 63(10): 895-906.
180. Lobb CJ, Wilson CJ, Paladini CA. A dynamic role for GABA receptors on the firing pattern of midbrain dopaminergic neurons. JNeuro-physiol. 2010; 104(1): 403-413.
181. Valenti O, Grace AA. Antipsychotic drug-induced increases in ventral tegmental area dopamine neuron population activity via activation of the nucleus accumbens-ventral pallidum pathway. Int J Neuropsycho- pharmacol. 2010; 13(7): 845-860.
182. Deister CA, Teagarden MA, Wilson CJ, Paladini CA. An intrinsic neuronal oscillator underlies dopaminergic neuron bursting. J Neuro-sci. 2009; 29(50): 15888-15897.
183. Omelchenko N, Sesack SR. Cholinergic axons in the rat ventral teg-mental area synapse preferentially onto mesoaccumbens dopamine neurons. J Comp Neurol. 2006; 494(6): 863-875.
184. Mena-Segovia J, Winn P, Bolam JP. Cholinergic modulation of mid-brain dopaminergic systems. Brain Res Rev. 2008; 58(2): 265-271.
185. Stansley BJ, Yamamoto BK. L-dopa-induced dopamine synthesis and oxidative stress in serotonergic cells. Neuropharmacology. 2013; 67: 243-251.
186. Huang M, Dai J, Meltzer HY. 5-HT(2A) and 5-HT(2C) receptor stimulation are differentially involved in the cortical dopamine efflux-Studied in 5-HT(2A) and 5-HT(2C) genetic mutant mice. Eur J Pharmacol. 2011; 652(1 - 3): 40-45.
187. Fletcher PJ, Le AD, Higgins GA. Serotonin receptors as potential targets for modulation of nicotine use and dependence. Prog Brain Res. 2008; 172: 361-383.
188. Lanteri C, Salomon L, Torrens Y, Glowinski J, Tassin JP. Drugs of abuse specifically sensitize noradrenergic and serotonergic neurons via a non - dopaminergic mechanism. Neuropsychopharmacology. 2008; 33(7): 1724-1734.
189. Valentini V, Piras G, De Luca MA, Perra V, Bordi F, Borsini F, et al. Evidence for a role of a dopamine/5-HT6 receptor interaction in cocaine reinforcement. Neuropharmacology. 2013; 65: 58-64.
190. Goldstein LE, Rasmusson AM, Bunney BS, Roth RH. The NMDA glycine site antagonist (+)-HA-966 selectively regulates conditioned stress-induced metabolic activation of the mesoprefrontal cortical do-pamine but not serotonin systems: a behavioral, neuroendocrine, and neurochemical study in the rat. J Neurosci. 1994; 14(8): 4937-4950.
191. Parkitna JR, Sikora M, Golda S, Golembiowska K, Bystrowska B, Engblom D, et al. Novelty - seeking behaviors and the escalation of alcohol drinking after abstinence in mice are controlled by metabo-tropic glutamate receptor 5 on neurons expressing dopamine d1 receptors. Biol Psychiatry. 2013; 73(3): 263-270.
192. Blythe SN, Atherton JF, Bevan MD. Synaptic activation of dendritic AMPA and NMDA receptors generates transient high - frequency firing in substantia nigra dopamine neurons in vitro. JNeurophysiol. 2007; 97(4): 2837-2850.
193. Zhang J, Xu TX, Hallett PJ, Watanabe M, Grant SG, Isacson, et al. PSD-95 uncouples dopamine-glutamate interaction in the D1/PSD-95/NMDA receptor complex. J Neurosci. 2009; 29(9): 2948-2960.
194. Zarrindast MR, Khalifeh S, Rezayof A, Rostami P, Aghamohammadi Sereshki A, Zahmatkesh M. Involvement of rat dopaminergic system of nucleus accumbens in nicotine-induced anxiogenic-like behaviors. Brain Res. 2012; 1460: 25-32.
195. Markou A. Neurobiology of nicotine dependence. Philos Trans R Soc LondB Biol Sci. 2008; 363(1507): 3159-3168.
196. Grady SR, Salminen O, Laverty DC, Whiteaker P, Mcintosh JM, Collins AC, et al. The subtypes of nicotinic acetylcholine receptors on do-paminergic terminals of mouse striatum. Biochem Pharmacol. 2007; 74(8): 1235-1246.
197. Motevasseli T, Rezayof A, Zarrindast MR, Nayer-Nouri T. Role of ventral hippocampal NMDA receptors in anxiolytic-like effect of morphine. Physiol Behav. 2010; 101(5): 608-613.
198. Tepper JM, Lee CR. GABAergic control of substantia nigra dopaminergic neurons. Prog Brain Res. 2007; 160: 189-208.
199. Chuhma N, Tanaka KF, Hen R, Rayport S. Functional connectome of the striatal medium spiny neuron. J Neurosci. 2011; 31(4): 1183-1192.
200. Brazhnik E, Shah F, Tepper JM. GABAergic afferents activate both GABAA and GABAB receptors in mouse substantia nigra dopaminergic neurons in vivo. J Neurosci. 2008; 28(41): 10386-10398.
201. Labouebe G, Lomazzi M, Cruz HG, Creton C, Lujan R, Li M, et al.RGS2 modulates coupling between GABAB receptors and GIRK channels in dopamine neurons of the ventral tegmental area. Nat Neurosci. 2007; 10(12): 1559-1568.
202. Matsumoto M, Hikosaka O. Lateral habenula as a source of negative reward signals in dopamine neurons. Nature. 2007; 447(7148): 1111-1115.
203. Jhou TC, Geisler S, Marinelli M, Degarmo BA, Zahm DS. The meso- pontine rostromedial tegmental nucleus: A structure targeted by the lateral habenula that projects to the ventral tegmental area of Tsai and substantia nigra compacta. J Comp Neurol. 2009; 513(6): 566-596.
204. Lobb CJ, Wilson CJ, Paladini CA. High-frequency, short-latency disinhibition bursting of midbrain dopaminergic neurons. J Neuro-physiol. 2011; 105(5): 2501-2511.
205. Kaufling J, Veinante R Pawlowski SA, Freund-Mercier MJ, Barrot M. Afferents to the GABAergic tail of the ventral tegmental area in the rat. J Comp Neurol. 2009; 513(6): 597-621.
206. Bourdy R, Barrot M. A new control center for dopaminergic systems: pulling the VTA by the tail. Trends Neurosci. 2012; 35(11): 681-690.
207. Rubino T, Guidali C, Vigano D, Realini N, Valenti M, Massi P, et al. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology. 2008; 54(1): 151-160.
208. Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Drago F, et al. Altered responses of dopamine D3 receptor null mice to ex-citotoxic or anxiogenic stimuli: Possible involvement of the endocan-nabinoid and endovanilloid systems. Neurobiol Dis. 2009; 36(1): 70-80.
209. Wu WC, Wang Y, Chai CY. Acute effects of the cannabinoid receptor agonist WIN55212-2 on dopamine release in rat: an in vivo electrochemical study. Chin J Physiol. 2008; 51(3): 152-159.
210. Kortleven C, Fasano C, Thibault D, Lacaille JC, Trudeau LE. The en-docannabinoid 2-arachidonoylglycerol inhibits long-term potentia-tion of glutamatergic synapses onto ventral tegmental area dopamine neurons in mice. Eur J Neurosci. 2011; 33(10): 1751-1760.
211. Melis M, Muntoni AL, Pistis M. Endocannabinoids and the processing of value-related signals. Front Pharmacol. 2012; 3: 7.
212. Zarrindast MR, Mahboobi S, Sadat-Shirazi MS, Ahmadi S. Anxio- lytic-like effect induced by the cannabinoid CB1 receptor agonist, arachydonilcyclopropylamide (ACPA), in the rat amygdala is mediated through the D1 and D2 dopaminergic systems. J Psychopharma-col. 2011; 25(1): 131-140.
213. Olianas MC, Dedoni S, Onali P. Potentiation of dopamine D1-like receptor signaling by concomitant activation of delta-and mu-opioid receptors in mouse medial prefrontal cortex. Neurochem Int. 2012; 61(8): 1404-1416.
214. Willuhn I, Wanat MJ, Clark JJ, Phillips PE. Dopamine signaling in the nucleus accumbens of animals self - administering drugs of abuse. Curr Top Behav Neurosci. 2010; 3: 29-71.
215. Fu Z, Yang H, Xiao Y, Zhao G, Huang H. The gamma-aminobutyric acid type B (GABAB) receptor agonist baclofen inhibits morphine sensitization by decreasing the dopamine level in rat nucleus accum-bens. Behav Brain Funct. 2012; 8: 20.
216. Mazei-Robison MS, Koo JW, Friedman AK, Lansink CS, Robison AJ, Vinish M, et al. Role for mTOR signaling and neuronal activity in morphine-induced adaptations in ventral tegmental area dopamine neurons. Neuron. 2011; 72(6): 977-990.
217. Georges F, Le Moine C, Aston-Jones G. No effect of morphine on ventral tegmental dopamine neurons during withdrawal. J Neurosci. 2006; 26(21): 5720-5726.
218. Passani MB, Giannoni P, Bucherelli C, Baldi E, Blandina P. Histamine in the brain: beyond sleep and memory. Biochem Pharmacol. 2007; 73(8): 1113-1122.
219. Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev. 2008; 88(3): 1183-1241.
220. Yorgason JT, Espana RA, Konstantopoulos JK, Weiner JL, Jones SR. Enduring increases in anxiety-like behavior and rapid nucleus ac-cumbens dopamine signaling in socially isolated rats. Eur J Neurosci. 2013; 37(6): 1022-1031.
221. De Oliveira AR, Reimer AE, Brandao ML. Role of dopamine receptors in the ventral tegmental area in conditioned fear. Behav Brain Res. 2009; 199(2): 271-277.
222. Martinez RC, Oliveira AR, Macedo CE, Molina VA, Brandao ML. Involvement of dopaminergic mechanisms in the nucleus accumbens core and shell subregions in the expression of fear conditioning. Neu-rosci Lett. 2008; 446(2 - 3): 112-116.
223. Li W, Doyon WM, Dani JA. Acute in vivo nicotine administrationenhances synchrony among dopamine neurons. Biochem Pharmacol. 2011; 82(8): 977-983.
224. Grilli M, Zappettini S, Zoli M, Marchi M. Pre-synaptic nicotinic and D receptors functionally interact on dopaminergic nerve endings of rat and mouse nucleus accumbens. J Neurochem. 2009; 108(6): 1507-1514.
225. Stuber GD, Sparta DR, Stamatakis AM, Van Leeuwen WA, Hard- joprajitno JE, Cho S, et al. Excitatory transmission from the amygdala to nucleus accumbens facilitates reward seeking. Nature. 2011; 475(7356): 377-380.
226. Sarantis K, Matsokis N, Angelatou F. Synergistic interactions of do-pamine D1 and glutamate NMDA receptors in rat hippocampus and prefrontal cortex: involvement of ERK1/2 signaling. Neuroscience. 2009; 163(4): 1135-1145.
227. Behr GA, Da Motta LL, De Oliveira MR, Oliveira MW, Hoff ML, Silvestrin RB, et al. Decreased anxiety-like behavior and locomotor/ exploratory activity, and modulation in hypothalamus, hippocampus, and frontal cortex redox profile in sexually receptive female rats after short-term exposure to male chemical cues. Behav Brain Res. 2009; 199(2): 263-270.
228. Nascimento Hackl LP, Carobrez AP. Distinct ventral and dorsal hippocampus AP5 anxiolytic effects revealed in the elevated plus-mazetask in rats. Neurobiol Learn Mem. 2007; 88(2): 177-185.
229. Roohbakhsh A, Keshavarz S, Hasanein P, Rezvani ME, Moghaddam AH. Role of endocannabinoid system in the ventral hippocampus of rats in the modulation of anxiety-like behaviours. Basic Clin Pharmacol Toxicol. 2009; 105(5): 333-338.
230. Laviolette SR, Grace AA. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci. 2006; 63(14): 1597-1613.
231. Giuffrida A, Seillier A. New insights on endocannabinoid transmission in psychomotor disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 38(1): 51-58.
232. Oleson EB, Beckert MV, Morra JT, Lansink CS, Cachope R, Abdullah RA, et al. Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum. Neuron. 2012; 73(2): 360-373.
233. Martin AB, Fernandez-Espejo E, Ferrer B, Gorriti MA, Bilbao A, Navarro M, et al. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology. 2008; 33(7): 1667-1679.